Kevin McArdle

Kevin has extensive experience in clinical stage biotech/regenerative medicine companies and commercial stage medical technology companies. Prior to joining Cheetah Medical he was CFO of Histogenics Corporation where he led the company through its initial public offering in 2014. Prior to joining Histogenics, Mr. McArdle was contract Chief Financial Officer for Avedro, Inc. and INVO Bioscience, Inc., two life science companies. Mr. McArdle also started two seed-stage technologies in the fields of cardiac resynchronization therapy.